Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 24, Issue 36, Pages 4152-4163
Publisher
Baishideng Publishing Group Inc.
Online
2018-09-25
DOI
10.3748/wjg.v24.i36.4152
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study
- (2018) Hwi Young Kim et al. BMC CANCER
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib
- (2018) Sébastien Mulé et al. RADIOLOGY
- Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol
- (2018) Andrea Casadei Gardini et al. TUMORI
- Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
- (2017) Andrea Casadei Gardini et al. EUROPEAN JOURNAL OF CANCER
- Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization
- (2017) Sangheun Lee et al. Hepatology International
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma
- (2017) Eileen L. Yoon et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma
- (2017) Bin-Yan Zhong et al. RADIOLOGY
- Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
- (2017) Giovan Giuseppe Di Costanzo et al. Targeted Oncology
- Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib
- (2017) Alberto Lué et al. Oncotarget
- Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib
- (2017) Jessica Howell et al. Oncotarget
- Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis
- (2017) Ping Wang et al. Expert Review of Gastroenterology & Hepatology
- MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways
- (2016) Yanmin Xu et al. CANCER LETTERS
- Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1α—Final results of the ALICE-2 study.
- (2016) Luca Faloppi et al. JOURNAL OF CLINICAL ONCOLOGY
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma
- (2016) Giovan Giuseppe Di Costanzo et al. Targeted Oncology
- eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
- (2016) Omar Abdel-Rahman et al. Expert Review of Gastroenterology & Hepatology
- MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma
- (2016) Naoshi Nishida et al. Liver Cancer
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- (2015) P F Ferrucci et al. BRITISH JOURNAL OF CANCER
- Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib
- (2015) Andrea Casadei Gardini et al. EXPERT OPINION ON PHARMACOTHERAPY
- Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma
- (2015) Giovan Giuseppe Di Costanzo et al. Future Oncology
- Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib
- (2015) Kazuko Sakai et al. Oncotarget
- MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway
- (2015) Changjun He et al. Oncotarget
- MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib
- (2015) Paola Stiuso et al. Molecular Therapy-Nucleic Acids
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
- (2014) B. Hu et al. CLINICAL CANCER RESEARCH
- VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
- (2014) Mario Scartozzi et al. INTERNATIONAL JOURNAL OF CANCER
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma
- (2014) Benedek Gyöngyösi et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic
- (2014) Daniel E Carvajal-Hausdorf et al. LABORATORY INVESTIGATION
- MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma
- (2014) Valentina Vaira et al. LIVER INTERNATIONAL
- Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2014) Leonardo Gomes da Fonseca et al. MEDICAL ONCOLOGY
- Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib
- (2014) M. Ronot et al. ONCOLOGIST
- An Updated Meta-Analysis of Randomized Controlled Trials Assessing the Effect of Sorafenib in Advanced Hepatocellular Carcinoma
- (2014) Songlin Peng et al. PLoS One
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
- (2014) E. Horwitz et al. Cancer Discovery
- Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
- (2013) Kaoru Tsuchiya et al. CANCER
- Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib
- (2013) D. Chen et al. EJSO
- Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2013) Takahide Nakazawa et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
- (2013) Z. Kan et al. GENOME RESEARCH
- Identification of driver genes in hepatocellular carcinoma by exome sequencing
- (2013) Sean P. Cleary et al. HEPATOLOGY
- Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib
- (2013) Sun Young Shin et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma
- (2013) Nicola Personeni et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
- (2013) Jie Sheng Chu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound
- (2013) Maria Assunta Zocco et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US
- (2013) Katsutoshi Sugimoto et al. LIVER INTERNATIONAL
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- (2012) T. Pressiani et al. ANNALS OF ONCOLOGY
- Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
- (2012) S Hagiwara et al. BRITISH JOURNAL OF CANCER
- Molecular mechanisms of sorafenib action in liver cancer cells
- (2012) Melchiorre Cervello et al. CELL CYCLE
- Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy
- (2012) Y.-Y. Shao et al. CLINICAL CANCER RESEARCH
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
- (2012) Ann-Lii Cheng et al. EUROPEAN JOURNAL OF CANCER
- Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma
- (2012) Dominik Bettinger et al. HEPATOLOGY
- FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
- (2012) Tokuzo Arao et al. HEPATOLOGY
- Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
- (2012) Taiga Otsuka et al. HEPATOLOGY RESEARCH
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET
- Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy
- (2012) Z.-Z. Lin et al. ONCOLOGIST
- Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma
- (2012) Ronald Koschny et al. ONCOLOGY
- Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
- (2011) A. Hollebecque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma
- (2011) Changchun Zhou et al. FEBS LETTERS
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma
- (2011) Koji Miyahara et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
- (2011) Chao-Yu Hsu et al. JOURNAL OF HEPATOLOGY
- Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
- (2011) Wei-Tien Tai et al. JOURNAL OF HEPATOLOGY
- Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib
- (2011) Jae Hoon Lee et al. LIVER INTERNATIONAL
- The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
- (2011) T. Yau et al. ONCOLOGIST
- Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
- (2010) Augusto Villanueva et al. Annual Review of Medicine
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study
- (2010) Wei-Wen Su et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease
- (2010) Valter Donadon et al. LIVER INTERNATIONAL
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2010) B. Vincenzi et al. ONCOLOGIST
- Angiopoietin-2: Development of inhibitors for cancer therapy
- (2009) Bo Hu et al. Current Oncology Reports
- Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
- (2008) M. Scartozzi et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started